A 32-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and night sweats. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli. He is started on standard first-line anti-TB therapy (HRZE). After 2 months of treatment, repeat sputum smear remains positive despite good adherence. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **treatment failure** — defined as persistent sputum positivity after 5 months of directly observed therapy (DOT) with a standard first-line regimen. Despite documented adherence, microbiological failure indicates either: - **Drug-resistant TB** (MDR-TB or XDR-TB) - **Malabsorption** of drugs - **Inadequate drug levels** (rare with DOT) ## Management Algorithm for Treatment Failure ```mermaid flowchart TD A[Sputum positive at month 2 of HRZE]:::outcome --> B{Adherence documented?}:::decision B -->|Yes| C[Suspect drug-resistant TB]:::urgent B -->|No| D[Reinforce DOT + counseling]:::action C --> E[Perform DST immediately]:::action E --> F{Results available?}:::decision F -->|Pending| G[Start second-line therapy empirically]:::action F -->|Confirmed MDR| H[Continue second-line regimen]:::action G --> I[Adjust based on DST results]:::action ``` ## Key Point: **Treatment failure at month 2 with documented adherence mandates DST to guide second-line therapy.** Continuing first-line drugs or modifying first-line regimens alone will not address underlying drug resistance. ## High-Yield Facts: | Finding | Implication | |---------|-------------| | Sputum positive at month 2 of DOT | Treatment failure | | Documented adherence | Rules out non-adherence as cause | | Cavitary disease + positive sputum at month 2 | High risk for MDR-TB | | DST required | Guides second-line regimen selection | ## Clinical Pearl: **Do not delay DST.** While awaiting results, empirical second-line therapy (fluoroquinolone + bedaquiline + linezolid or similar) should be initiated in high-burden TB settings to prevent further transmission and disease progression. DST results then allow tailoring of the regimen. ## Mnemonic: TREATMENT FAILURE RESPONSE - **T**est for drug resistance (DST) immediately - **R**ule out malabsorption, drug interactions - **E**mpirically start second-line therapy (if DST pending) - **A**djust regimen based on DST results - **T**reatment duration typically 20 months for MDR-TB [cite:Harrison 21e Ch 158]